Extrathyroidal effects of propylthiouracil and carbimazole on serum T4, T3, reverse T3 and TRH-induced TSH-release in man.
A possible extrathyroidal effect of propylthiouracil (PTU) and carbimazole on serum levels of thyroxine (T4), triiodothyronine (T3), 3,3',5'-triiodothyronine (reverse T3) and on thyrotrophin-releasing hormone (TRH) induced thyrotrophin (TSH) release was estimated in 19 patients with severe hypothyroidism treated with T4. During PTU medication a significant decrease in serum T3 from 90 +/- 16 (SD) to 79 +/- 23 ng/100 ml (P less than 0.01) and a reciprocal increase in serum reverse T3 from 51 +/- 14 (SD) to 58 +/- 20 ng/100 ml (P less than 0.025) were found. No significant changes in serum T4, basal serum TSH or response to TRH could be demonstrated. Carbimazole did not change any of the parameters studied.
D000328:Adult; D000368:Aged; D002231:Carbimazole / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011441:Propylthiouracil / Q000494:pharmacology*; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood* / Q000627:therapeutic use; D014284:Triiodothyronine / Q000097:blood*
D014284:Triiodothyronine; D013973:Thyrotropin-Releasing Hormone; D011441:Propylthiouracil; D002231:Carbimazole; D013972:Thyrotropin; D013974:Thyroxine